Sanjay Singh

Dr. Sanjay Singh

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Carbon
Verified
Journal Article
Closed access
SSSandeep Sharma
Sandeep Sharma
SSSanjay Singh
Sanjay Singh
AGAshok K. Ganguli
Ashok K. Ganguli
VSVijayakumar Shanmugam
Vijayakumar Shanmugam

1 February 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SSSanjay Singh
Sanjay Singh
APAshutosh Pathak
Ashutosh Pathak
AKAwadhesh Kumar
Awadhesh Kumar
MRMohibur Rahman
Mohibur Rahman
ASAvinash Singh
Avinash Singh
KPKashi N. Prasad
Kashi N. Prasad
Transmissible colistin resistance gene, mcr-1 has breached the one of the last line of defense for treatment of infections caused by carbapenem-resistant Enterobacteriaceae.…

4 October 2022 in Tuberculosis
Verified
Journal Article
Closed access
PSPrem Shankar
Prem Shankar
SSSanjay Singh
Sanjay Singh
GBGunavanthi D. Boorgula
Gunavanthi D. Boorgula
TGTawanda Gumbo
Tawanda Gumbo
SHScott Heysell
Scott Heysell
SSShashikant Srivastava
Shashikant Srivastava

13 May 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
SSSanjay Singh
Sanjay Singh
Jann-Yuan WangJann-Yuan Wang
Jann-Yuan Wang
SHScott K. Heysell
Scott K. Heysell
PMPamela J. McShane
Pamela J. McShane
CWCarly Wadle
Carly Wadle
SSShashikant Srivastava
Shashikant Srivastava

1 September 2018 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Closed access
MRMohibur Rahman
Mohibur Rahman
Chiranjay MukhopadhyayChiranjay Mukhopadhyay
Chiranjay Mukhopadhyay
RRRavi Prakash Rai
Ravi Prakash Rai
SSSanjay Singh
Sanjay Singh
SGShefali Gupta
Shefali Gupta
KPKashi Nath Prasad
Kashi Nath Prasad

17 December 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
SSSanjay Singh
Sanjay Singh
TGTawanda Gumbo
Tawanda Gumbo
Jann-Yuan WangJann-Yuan Wang
Jann-Yuan Wang
GBGunavanthi D Boorgula
Gunavanthi D Boorgula
ABAndrew Burke
Andrew Burke
SSShashikant Srivastava
Shashikant Srivastava
Background: Guideline-based therapy (GBT) for Mycobacterium abscessus (Mab) lung disease achieves sputum culture conversion (SCC) rates of 35%. This poor GBT efficacy is mirrored in the hollow fiber system model of Mab (HFS-Mab). While imipenem is part of GBT, its biologic effect, with or without β-lactamase inhibitors, is unproven. Methods: We performed imipenem-relebactam minimum inhibitory concentration (MIC) in 122 Mab isolates, and an exposure-response study in the HFS-Mab using human intrapulmonary pharmacokinetics. The percentage of time that concentration persisted above the MIC (TMIC), mediating maximal effect in the HFS-Mab, was used as the exposure target for dose finding in a Monte Carlo experiment including 10 000 virtual patients. For real-world evidence, we performed a patient, intervention (imipenem), comparison (no β-lactam), and outcome (SCC) (PICO) analysis. Results: Imipenem killed 1.32 log10 colony-forming units/mL below the day 0 level in HFS-Mab. The average target exposure for imipenem was a TMIC of 47.9% (SD, 9.77%). Infusion of 1 g every 6 hours achieved the target in >90% of virtual patients in Monte Carlo experiments. The pharmacokinetic-pharmacodynamic MIC break point was 1 mg/L. In PICO analyses, the median time to SCC was 470 days in comparators, 311 days for imipenem added on to a failing regimen, and 37 days in newly treated patients (P = .049). The odds ratio for SCC when imipenem was part of the initial regimen, versus comparators, was 12.5 (95% confidence interval, 1.47­–84.55). No patients receiving imipenem experienced treatment-limiting adverse events, compared with 2 of 7 comparators (P = .046). Middlebrook 7H9 broth MIC distribution, read at 24 hours, was better correlated with patient responses than cation-adjusted Mueller-Hinton broth. Conclusions: Imipenem demonstrated biologic effect in the HFS-Mab and in patients. Imipenem-relebactam doses of 1 g every 6 hours are recommended.